Xyz interventions: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Andersen-Tawil syndrome}}
{{XYZ}}
{{CMG}}; {{AE}} {{VKG}}
{{CMG}}; {{AE}}  


==Overview==
==Overview==
Line 8: Line 8:
OR
OR


Cardioverter-defibrillator is not the first-line treatment option for patients with Andersen-Tawil syndrome (ATS) . Cardioverter-defibrillator is usually reserved for patients with tachycardia-induced syncope.
[name of intervention] is not the first-line treatment option for patients with [disease name]. [name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].


OR
OR

Latest revision as of 18:45, 28 January 2021

Template:XYZ Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no recommended therapeutic interventions for the management of [disease name].

OR

[name of intervention] is not the first-line treatment option for patients with [disease name]. [name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.

OR

[Name of intervention] is the mainstay of treatment for [disease or malignancy].

Indications

The mainstay of treatment for TT is medical therapy.

References

Template:WH Template:WS